FDA DrugClass IINotable

FDA Recall: Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Single dose only, Rx Only, M

Date: 2026-04-15
Brand: Cipla USA, Inc.
Category: Drug
FDA Class: Class II

Description

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

Hazard

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

View original recall →
Share:

Related Recalls

2026-04-22 · FDA_DRUG
FDA Recall: Cinacalcet Hydrochloride Tablets, 90 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Cipla Ltd.
Cipla USA, Inc.
2026-04-22 · FDA_DRUG
FDA Recall: Cinacalcet Hydrochloride Tablets, 60 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Cipla Ltd.
Cipla USA, Inc.
2026-04-22 · FDA_DRUG
FDA Recall: Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Cipla Ltd.
Cipla USA, Inc.
2026-04-15 · FDA_DRUG
FDA Recall: Lanreotide Injection, 120 mg*/0.5 mL, Box contains 1 Pre-filled syringe and 1 safety needle, Single
Cipla USA, Inc.